VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Tuesday, highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development. The company aims to advance its lead BiTAC-TCE candidate, VXA-102, to investigational new drug (IND) or clinical trial application (CTA) readiness by early 2028.
Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
BiTAC is a registered trademark of VERAXA Biotech GmbH. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
For more information, the full press release is available at https://ibn.fm/xTF5q.
The company's newsroom can be accessed at http://ibn.fm/VRXA for the latest news and updates.
